Login to Download
PDF version

Advanced Biohealing Changes Name to Shire Regenerative Medicine

  Shire plc (San Diego, CA) announced that Advanced BioHealing, Inc, which was acquired by Shire in 2011 as a wholly-owned subsidiary focused on regenerative medicine, has changed its name to Shire Regenerative Medicine, Inc, effective immediately. The name change follows a recent announcement that the company plans to build a regenerative medicine campus in San Diego to expand its operational footprint and presence in the area over the next several years.

  Shire Regenerative Medicine is focused on developing and delivering solutions that support Dermagraft®, is a bio-engineered skin substitute indicated for use in the treatment of full-thickness diabetic foot ulcers.

  Visit www.shire.com for more information.

Keraplast Extends Wound Care Distribution Network to Turkey

  Keraplast Technologies, LLC (San Antonio, TX) has entered into an agreement with Gramatek, Ltd for distribution of their advanced wound care products to hospitals and wound care centers throughout Turkey. Partnering with Gramatek provides Keraplast access to hospitals, clinics, and strategic points of service centers throughout key regional areas of Turkey.

  Visit www.keraplast.com for more information.

Cytomedix Extends Exclusivity Period With Top 20 Global Pharmaceutical Companies

  Cytomedix, Inc (Gaithersburg, MD) announced an extension of the exclusivity period and an agreement with the top 20 global pharmaceutical companies to negotiate a distribution agreement of the AutoloGel System in the US chronic wound care market.

  The parties agreed to extend the exclusivity period until August 30, 2012, and are negotiating the material terms and provisions of a distribution agreement with sales expected to commence under such arrangement immediately upon execution. The distribution arrangement will include mutual options to convert the arrangement into an exclusive license and supply agreement.

  The exclusivity extension and agreement represent a continuation of the discussion of commercialization opportunities in the US chronic wound care market previously disclosed by the company.

  Visit www.cytomedix.com for more information.

Thermogenesis Announces Sale of Cryoseal® Sale of Product Line to Asahi

  ThermoGenesis Corp (Rancho Cordova, CA), announced Asahi Kasei Medical Co, Ltd, exercised its option to purchase the company’s CryoSeal Fibrin Sealant System wound care product line for $2 million in cash, effective June 30, 2012.

  Visit www.thermogenesis.com for more information.

Patent Issued for Vomaris’ New Wound Dressing

  Vomaris Innovations, Inc (Chandler, AZ) has been granted another patent (US Pat. No. 8,224,439) related to its bioelectric technology surrounding the use of devices that rely upon reducing and oxidizing agents to treat biologic tissue and promote healing. Procellera® is the first totally self-contained, conformable, cut-to-fit, electrically active wound dressing in the world, according to the company. The extremely versatile technology spans multiple health care industries.

  Visit www.vomaris.com for more information.

Derma Sciences Receives CE Mark for MEDIHONEY® HCS

  Derma Sciences, Inc (Princeton, NJ) announced receipt of the CE Mark for the company’s patented MEDIHONEY® hydrogel colloidal sheet (HCS) dressings. With this determination, the entire current line of MEDIHONEY products has CE markings.

  The line of patented wound care dressings containing Active Leptospermum Honey from New Zealand, which has qualities that make it ideal for the management of chronic and acute wounds and burns.